STAT+: LabCentral, a crucial incubator for local drug discovery, is slated to grow amid industry slowdown
CAMBRIDGE — Vietnamese-born entrepreneur Jean Pham is “graduating” from LabCentral, a biotech launchpad on the…
Category: Medicine
UnitedHealth’s rehab restrictions, Texas medical school drama, and health care’s biggest profits
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of…
An ugly fight over care for the poor in Texas
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles
Good morning, everyone, and welcome to another working week, and a new year, as well….
STAT+: Here’s who’s profiting the most in health care
For all the flack they get, the country’s four biggest pharmacy benefit managers reported a…
Opinion: Buprenorphine, autism diagnoses, and long Covid: the most-read First Opinion essays of 2023
In a year of abortion restrictions, biotech industry upheaval, and revolutionary drug approvals, First Opinion…
Opinion: There’s a less intimidating alternative to EpiPens for dangerous allergic reactions. Why won’t the FDA approve it?
My son Thomas has carried around a needle since he entered kindergarten at the age…
.jpg)
Fights over methadone, harm reduction, and more: 3 addiction stories to watch in 2024
The U.S. drug crisis is as bad as it’s ever been, and there are few…
We wish we’d written that: STAT staffers share their favorite stories of 2023
It’s time to take stock of the year that was in health and science: the…
JPM Healthcare Conference 2024
The annual J.P. Morgan Healthcare Conference, the largest event of its kind, will take place…
Opinion: Gaza, Ukraine, and other conflicts could be accelerating antibiotic resistance
In recent months, evidence suggests, the war in Ukraine and the ongoing conflict in Gaza have led to…
STAT+: 3 health policies states are taking on in 2024
For most states, the new year means a new legislative session. STAT’s taking a look…
Renamed, common liver diseases might get fairer shake at treatment, researchers hope
A slate of liver diseases got a rebrand this year. Experts hope the change can…
STAT+: UnitedHealth used secret rules to restrict rehab care for seriously ill Medicare Advantage patients
Health insurance giant UnitedHealth Group used secret rules to restrict access to rehabilitation care requested…
STAT stories you might have missed in 2023
There’s an old story in journalism, and it goes like this: A reporter is asked,…
STAT+: Apple Watches are back on sale while federal court reviews patent suit
Apple Watches are back on the market. In a last minute win for the company,…
Quitting alcohol — or even drinking less — reduces risk of oral cavity and esophageal cancer, per new analysis
Reducing or eliminating alcohol consumption reduces the risk of developing oral cavity and esophagus cancers,…
.jpg)
STAT+: Philips pays $2.4 million for allegedly giving kickbacks to sleep labs
Philips agreed to pay $2.4 million to settle allegations that the free masks it gave…
STAT+: Cytokinetics heart drug aficamten succeeds in pivotal study
An experimental medicine from Cytokinetics significantly improved exercise capacity for patients with a rare, progressive…
STAT+: What comes after Wegovy? The quest to eradicate obesity
About a decade ago, after becoming obese, Jacob Petersen lost weight so quickly that some…
Opinion: Remembering Betty Rollin, who told her breast surgeon that post-operative appearance mattered to her—and other women
Women who had undergone disfiguring surgery for breast cancer, according to one surgeon in the…
Violet CEO on measuring clinician inclusiveness: ‘It’s almost like a credit score’
PHOENIX, Ariz. — Gaurang Choksi is the founder and CEO of Violet, a health equity…
STAT+: 3 FDA staffers to watch in 2024
WASHINGTON — The Food and Drug Administration has a lot on its plate in 2024…
Opinion: People with food insecurity deserve better nutrition education
Since spring 2022, a flood of migrants fleeing political instability in Venezuela — about 136,000…
STAT+: 3 issues to watch in pharma in 2024
As another year comes to an end and the world seems to hit the proverbial…
STAT+: Complications spiked 25% in hospitals bought by private equity
There’s ample evidence that private equity buyouts in health care drive up costs. A new…
Opinion: Does food as medicine help patients with diabetes? Here’s what a new clinical trial says
Food-as-medicine programs that address food insecurity and diet-related chronic diseases have drawn widespread attention from…
STAT+: With Biden finalizing an Apple Watch ban, Apple needs to decide its future in health
An import ban of certain Apple Watches officially goes into effect on Tuesday, after the…
STAT+: Bristol Myers will pay $4.1 billion for cancer startup RayzeBio
Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into…
STAT+: New weight loss drugs have proven their effectiveness. Now researchers want to know how to best use them
LONDON — Starting in the new year, a team of researchers in the U.K. and…
STAT+: 3 CRISPR advances to watch in 2024
Life in the CRISPR lane tends to move at lightning speed. This year saw the…
STAT+: 3 medtech trends to watch in 2024
It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was…
Opinion: STAT readers on patient advocacy, the utility of diagnostic tests, and more
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
STAT+: FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear
The Food and Drug Administration issued a change to the warning label for Legend Biotech…
STAT+: Venture capital is still pouring into drug research despite Medicare price negotiation
WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s…
Morning Rounds: Our newsroom’s favorite stories of 2023
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
The clock is ticking, and cytokinetics is running out of December
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud
And so, another working week will soon come to a close. Not a moment too…
STAT+: Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion
Bristol Myers Squibb said Friday that it will acquire Karuna Therapeutics, a developer of medicines…
Opinion: The unique pain and joy of celebrating Christmas with a child in the pediatric intensive care unit
In the days leading up to Christmas in the pediatric intensive care unit (PICU), medical…
STAT+: AAFP’s CEO on how to keep primary care doctors in the field
In ten years, the United States could be short as many as 48,000 primary care…
3 issues to watch in global health in 2024
As we enter the fifth year of this challenging decade, life finally appears to be…
FDA approves AstraZeneca, Ionis treatment for rare nerve disease
The Food and Drug Administration approved a novel medicine for a rare and devastating nerve…
Listen: 2023 in review, CEO report cards, and a look at the year ahead
What does it mean to a bad CEO? Can biotech endure another election year? And…
Health data breaches hit an all-time high in 2023
Odds are, you’ve gotten at least one of the unnerving letters in your mailbox this…
Morning Rounds: Why health care costs are nearly a fifth of the GDP
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
BioMarin appeases an activist
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer
Good morning, everyone. Damian Garde here, filling in for Ed Silverman in a week customarily…
STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace
To ring the register, a pharmaceutical company may create a patent thicket, which involves filing…
Obesity drugs’ next tests, and rising threats: 3 chronic disease stories to watch
Chronic disease is, by its very definition, omnipresent. But changes year to year have the…